Please login to the form below

Not currently logged in
Email:
Password:

GSK signs biopharma deal with Lonza

GlaxoSmithKline will support the development of its biopharmaceutical pipeline in a new agreement with Lonza

Lonza has agreed to supply GlaxoSmithKline(GSK) with manufacturing capacity for five early stage monoclonal antibodies to support the development of GSK's biopharmaceutical pipeline.

The agreement will see Lonza – a major supplier to the pharmaceutical, healthcare and life science industries – manufacture clinical trial batches of five compounds currently in phase I and II development for GSK.

Flexible capacity will also be provided by Lonza allowing GSK to respond to future progress in the development of the antibodies.

Others details, including financial terms, were not disclosed.

Speaking about the agreement, Dr Stephan Kutzer, chief operating officer of Lonza Custom Manufacturing said: "We see this as a relationship that will bring significant benefits to both parties."

As well as providing manufacturing capacity for GSK, the deal will also see Lonza provide advice on GSK's plans to expand its own biopharmaceutical manufacturing capabilities. This includes the construction of a biopharmaceutical manufacturing facility within the UK.

"Our goal is to establish a portfolio of biopharmaceutical products that by 2015 consistently exceeds 20 per cent of our R&D pipeline," said Ian Tomlinson, head of biopharm research and development, GSK. "To make this a reality we need to ensure that we have the right resources in place, which include flexible and expert manufacturing capabilities, to enable us to ultimately create and deliver these future medicines to patients."

9th September 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Article
How will COVID-19 affect uptake of vaccinations against other diseases?...
Top 10 Reasons Why Virtual Collaboration and Medical Education Will Persist in the New Normal
Even after the pandemic is long behind us, virtual collaboration will become mainstay in Pharma....
Podcast
Living With Chronic Illness (Series one)...

Infographics